Biogen Alcyone acquisition grants access to implantable device, potentially easing RNA drug delivery for treatments like Spinraza.
Author: PharmaSignal News Desk
Arvinas out-license vepdegestrant with Pfizer, impacting their partnership and market strategy.
Roche 89bio deal involves a $2.4 billion acquisition, targeting MASH with a late-stage drug that could impact the market significantly.
A snapshot of August 2025’s top pharma and biopharma developments — highlighting $185.28B in deal value, four FDA approvals, and EMA’s regulatory focus on AI
Precigen FDA approval for Papzimeos granted without confirmatory trial, benefiting adult patients with recurrent respiratory papillomatosis.
AbbVie acquires bretisilocin for up to $1.2 billion, marking a significant move in psychedelic treatments.
LB Pharmaceuticals IPO raises $285M, marking the first major biotech IPO since February, focusing on schizophrenia treatment.
Novartis Monte Rosa partnership focuses on immunology, potentially worth $5.7 billion.
FDA guidance non-opioid pain medicines includes speedy approval pathways to address the opioid crisis with new drug options.
Sun Pharma Halol Plant faces an FDA export ban due to ongoing safety violations, affecting drug exports to the US.